Our results suggest that AXL signaling contributes to the aggressiveness of DDLPS and PLS, and that AXL is therefore a potential therapeutic target for treatment of these rare, yet devastating tumors. The gene discussed is AXL; the disease is pleomorphic liposarcoma.